In The Lancet Oncology, Robert Pirker and colleagues report on further analysis of the FLEX-study where they calculate an immunohistochemistry score (H score) to provide a more detailed assessment of EGFR protein expression and how this affects response to treatment with cetuximab in patients with advanced non-small-cell lung cancer (NSCLC). The H score takes into account the percentage of cells (0—100%) in each intensity category (0—3+) and computes a final score, on a continuous scale between 0...